Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

Nuri Tutar, Gokhan Metan, Ayşe Nedret Koç, Insu Yilmaz, Ilkay Bozkurt, Zuhal Ozer Simsek, Hakan Buyukoglan, Asiye Kanbay, Fatma Sema Oymak, Inci Gulmez, Ramazan Demir, Nuri Tutar, Gokhan Metan, Ayşe Nedret Koç, Insu Yilmaz, Ilkay Bozkurt, Zuhal Ozer Simsek, Hakan Buyukoglan, Asiye Kanbay, Fatma Sema Oymak, Inci Gulmez, Ramazan Demir

Abstract

Background: Invasive pulmonary aspergillosis (IPA) is an infection often occurring in neutropenic patients and has high mortality rates. In recent years, it has been reported that the incidence of IPA has also increased in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study is to investigate the clinical and demographic characteristics and treatment responses of IPA in patients with COPD.

Methods: Seventy-one patients with a positive culture of Aspergillus from lower respiratory tract samples were examined retrospectively. Eleven (15.4%) of these patients, affected with grade 3 or 4 COPD, had IPA.

Results: Aspergillus hyphae were detected in lung biopsy in three (27.3%) out of 11 patients and defined as proven IPA; a pathological sample was not taken in the other eight (72.7%) patients, and these were defined as probable IPA. Aspergillus isolates were identified as six cases of Aspergillusfumigatus and three of Aspergillusniger in nine patients, while two isolates were not identified at species level. While five patients required intensive care unit admission, four of them received mechanical ventilation. The most common finding on chest X-ray and computed tomography (CT) (respectively 63.6%, 72.7%) was infiltration. Amphotericin B was the initial drug of choice in all patients and five patients were discharged with oral voriconazole after amphotericin B therapy. Six patients (54.5%) died before treatment was completed.

Conclusions: IPA should be taken into account in the differential diagnosis particularly in patients with severe and very severe COPD presenting with dyspnea exacerbation, poor clinical status, and a new pulmonary infiltrate under treatment with broad-spectrum antibiotics and steroids.

Keywords: Aspergillosis; COPD; Chronic obstructive pulmonary disease; Invasive pulmonary aspergillosis.

References

    1. Chakrabarti A, Chatterjee SS, Das A, Shivaprakash MR. Invasive aspergillosis in developing countries. Med Mycol. 2011;49(Suppl 1):S35–S47.
    1. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases. Bone Marrow Transplant. 2012;47:846–854. doi: 10.1038/bmt.2011.178.
    1. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–625. doi: 10.1164/rccm.200401-093OC.
    1. Ribaud P, Chastang C, Latgé JP, Baffroy-Lafitte L, Parquet N, Devergie A, Espérou H, Sélimi F, Rocha V, Espérou H, Sélimi F, Rocha V, Derouin F, Socié G, Gluckman E. Survival and prognostic factors of invasive aspergillosis after allogenic bone marrow transplantation. Clin Infect Dis. 1999;28:322–330. doi: 10.1086/515116.
    1. Bulpa PA, Dive AM, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782–800. doi: 10.1183/09031936.00062206.
    1. Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, de Miguel J, Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010;16:870–877.
    1. Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect. 2012;18:403–408. doi: 10.1111/j.1469-0691.2011.03503.x.
    1. Philippe B, Ibrahim-Granet O, Prévost MC, Gougerot-Pocidalo MA, Sanchez Perez M, van der Meeren A, Latgé JP. Killing of Aspergillusfumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect Immun. 2003;71:3034–3042. doi: 10.1128/IAI.71.6.3034-3042.2003.
    1. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillusfumigatus hyphae by granulocyte colony-stimulating factor and gamma Interferon. Infect Immun. 1993;61:1185–1193.
    1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis. 2001;32:358–366. doi: 10.1086/318483.
    1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–535. doi: 10.1164/rccm.200703-456SO.
    1. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674–683. doi: 10.1086/590566.
    1. Verweij PE, Brandt ME. In: Manual of Clinical Microbiology. 9. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editor. Vol. 2. Washington: ASM Press; 2007. Aspergillus, Fusarium, and other opportunistic moniliaceous fungi; pp. 1802–1838.
    1. Leav BA, Fanburg B, Hadley S. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone. N Engl J Med. 2000;343:586. doi: 10.1056/NEJM200008243430818.
    1. Muquim A, Dial S, Menzies D. Invasive aspergillosis in patients with chronic obstructive pulmonary diseases. Can Respir J. 2005;12:199–204.
    1. He H, Ding L, Li F, Zhan Q. Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study. Crit Care. 2011;15:R5. doi: 10.1186/cc9402.
    1. Metan G, Koç AN, Atalay A, Kaynar LG, Ozturk A, Alp E, Eser B. The peformance of galactomannan antigen assay in the diagnosis of invasive pulmonary aspergillosis at different cutoff values. Mycoses. 2011;54(Suppl 2):80–81.
    1. Tanriover MD, Ascioglu S, Altun B, Uzun O. Galactomannan on the stage: prospective evaluation of the applicability in routine practice and surveillance. Mycoses. 2010;53:16–25.
    1. He H, Ding L, Chang S, Li F, Zhan Q. Value of consecutive galactomannan determinations for the diagnosis and prognosis of invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease. Med Mycol. 2011;49:345–351. doi: 10.3109/13693786.2010.521523.
    1. Gao X, Chen L, Hu G, Mei H. Invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease and the diagnostic value of combined serological tests. Ann Saudi Med. 2010;30:193–197. doi: 10.4103/0256-4947.62828.
    1. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannanantigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol. 2010;48:1255–1260. doi: 10.1128/JCM.02281-09.
    1. Metan G, Koç AN, Atalay A, Kaynar LG, Ozturk A, Alp E, Eser B. What should be the optimal cut-off of serum 1,3-β-D-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies? Scand J Infect Dis. 2012;44:330–336. doi: 10.3109/00365548.2011.638319.
    1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415. doi: 10.1056/NEJMoa020191.
    1. Saito T, Fujiuchi S, Tao Y, Sasaki Y, Ogawa K, Suzuki K, Tada A, Kuba M, Kato T, Kawabata M, Kurashima A, Sakatani M. NHO Pulmonary Fungosis Research Group. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection. 2012;40:661–667. doi: 10.1007/s15010-012-0322-x.
    1. Chu HY, Jain R, Xie H, Pottinger P, Fredricks DN. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13:105. doi: 10.1186/1471-2334-13-105.
    1. Blot SI, Taccone FS, van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, Dimopoulos G, Paiva JA, Misset B, Rello J, Vandewoude K, Vogelaers D. AspICU Study Investigators. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64. doi: 10.1164/rccm.201111-1978OC.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅